

FOR IMMEDIATE RELEASE

TSX VENTURE: HTL



HAMILTON THORNE FILES REVISED Q1 2011 FINANCIAL STATEMENTS

BEVERLY, MA and TORONTO, Ontario – June 29, 2011 - Hamilton Thorne Ltd. (TSX-V: HTL), a leading provider of advanced laser systems for the regenerative medicine, fertility and stem cell research markets, today announced that it has filed revised interim condensed consolidated financial statements for the first quarter ending March 31, 2011 to include additional footnote disclosure. This follows a review by the Ontario Securities Commission of the Company's first interim financial report prepared under International Financial Reporting Standards ("IFRS").

The Company's revised interim condensed consolidated financial statements disclose no change in assets, liabilities, equity, loss or cash flows from those previously filed. The revised interim condensed consolidated financial statements include the following additional footnote disclosures:

- A reconciliation of equity for the three months ended March 31, 2010 in note 19, as required by IFRS 1 *First-time Adoption of International Financial Reporting Standards*.
- A reconciliation of comprehensive income for the three months ended March 31, 2010 in note 19 as required by IFRS 1 *First-time Adoption of International Financial Reporting Standards*.

The revised interim condensed consolidated financial statements are available at www.sedar.com or on the Company's website at www.hamiltonthorne.com.

About Hamilton Thorne Ltd.

Hamilton Thorne provides novel solutions for Life Science that reduce cost, increase productivity as much as ten-fold, and enable research breakthroughs in regenerative medicine, stem cell research and fertility markets. The Company's new LYKOS™, Staccato™ and Stiletto™ laser systems offer significant scientific advantages in the fields of developmental biology, cancer research and advanced cell biology. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and procedures. Each member of Hamilton Thorne's family of products serves a different research purpose. By simply turning the microscope turret, researchers can have a new world of scientific capabilities at their fingertips.

Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard University, MIT, Yale, McGill University, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, Oxford University, and Cambridge.

Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.

Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements.

The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.

For more information, please contact:

David Wolf, President
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com

Lisa Rivero, Director of Corporate Communications
Hamilton Thorne Ltd.
978-921-2050
ir@hamiltonthorne.com